Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
07:00pm, Monday, 04'th Aug 2025
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
06:21pm, Monday, 04'th Aug 2025
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.96 per share a year ago.
BioMarin (BMRN) Q2 Revenue Jumps 16%
06:07pm, Monday, 04'th Aug 2025
BioMarin (BMRN) Q2 Revenue Jumps 16%
Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-G
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
09:00am, Friday, 01'st Aug 2025
SAN RAFAEL, Calif. , Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Monday, 28'th Jul 2025
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
09:00am, Tuesday, 22'nd Jul 2025
SAN RAFAEL, Calif. , July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conf
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
01:46pm, Wednesday, 16'th Jul 2025
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet
10:56am, Wednesday, 16'th Jul 2025
The consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Nasdaq Bull Market: 3 Historically Cheap Stocks That Can Easily Double Your Money
03:51am, Wednesday, 16'th Jul 2025
Though volatility is inherent in Wall Street, some years are more of a roller-coaster ride than others.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
10:42am, Monday, 14'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
10:46am, Friday, 11'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Thursday, 10'th Jul 2025
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
10:56am, Tuesday, 08'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
It is time for a move higher in biotech, says Mizuho's Jared Holz
06:29pm, Monday, 07'th Jul 2025
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
